Virological failure of patients on maraviroc-based antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1858-1864

  Raymond, Stéphanie ^a,b   Maillard, Anne ^c   Amiel, Corinne ^d   Peytavin, Gilles ^e   Trabaud, Mary Anne ^f   Desbois, Delphine ^g   Bellecave, Pantxika ^h   Delaugerre, Constance ⁱ   Soulie, Cathia ^j,k   Marcelin, Anne Geneviève ^j,k   Descamps, Diane ^e   Izopet, Jacques ^a,b   Reigadas, S ^l   Bellecave, P ^l   Pinson Recordon, P ^l   Fleury, H ^l   Masquelier, B ^l   Signori Schmuck, A ^l   Morand, P ^l   Bocket, L ^l   Mouna, L ^l   Andre P ^l   Tardy, J C ^l   Trabaud, M A ^l   Descamps, D ^e   Charpentier, C ^e   Peytavin, G ^e   Brun Vezinet F ^e   Haim Boukobza, S ^m   Roques, A M ^m   Soulie C ^k   Lambert Niclot, S ^k   Malet, I ^k   Wirden, M ^k   Fourati, S ^k   Marcelin, A G ^k   Calvez, V ^k   Flandre, P ^k   Assoumou, L ^k   Costagliola, D ^k   Morand Joubert, L ⁿ   Delaugerre, C ^o   Schneider, V ^p   Amiel, C ^p   Giraudeau, G ^l   Maillard, A ^l   Nicot, F ^l   Izopet, J ^l   more..

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d HÔPITAL TENON   (France)

^e BICHAT HOSPITAL   (France)

^f CROIX ROUSSE HOSPITAL   (France)

^g HÔPITAL PAUL BROUSSE   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l Bordeaux ^*  (France)

^m Paris Paul Brousse   (France)

ⁿ Saint Antoine Paris University Hospital Center   (France)

^o Saint Louis Institute Paris Diderot   (France)

^p Tenon   (France)

more..

Author keywords

CXCR4; Entry; HIV 1 tropism determination; Phenotypic assay; Resistance to maraviroc

Indexed keywords

MARAVIROC; ANTIRETROVIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; MULTICENTER STUDY; VIRAL TROPISM; VIROLOGICAL FAILURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TRIAZOLES; VIRAL LOAD; VIRAL TROPISM;

EID: 84930515956     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv026     Document Type: Article

References (32)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors:roles in viral entry, tropism, and disease. Annual Rev Immunol 1999; 17: 657-700.
2. Vandekerckhove LPR, Wensing AMJ, Kaiser R et al. European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis 2011; 11: 394-407.
3. Vandamme A-M, Camacho RJ, Ceccherini-Silberstein F et al. European recommendations for the clinical use of HIV drug resistance testing:2011 update. AIDS Rev 2011; 13: 77-108.
4. Fatkenheuer G,Nelson M, Lazzarin A et al. Subgroup analyses ofmaraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-55.
5. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
6. Archer J, Braverman MS, Taillon BE et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultradeep pyrosequencing. AIDS 2009; 23: 1209-18.
7. Westby M, Smith-Burchnell C, Mori J et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81: 2359-71.
8. Pugach P, Marozsan AJ, Ketas TJ et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361: 212-28.
9. Lewis M, Mori J, Simpson P et al. Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 871.
10. Lewis J, Simpson P, Delogne C et al. Genotypic analysis of the HIV-1 gp120 V3 loop for treatment-experienced patients enrolled into the MOTIVATE studies and who received maraviroc+optimized background therapy. In: Abstracts of the Seventeenth Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2010. Abstract 539.
11. Berro R, Klasse PJ, Jakobsen MR et al. V3 determinants of HIV-1 escape from the CCR5 inhibitors maraviroc and vicriviroc. Virology 2012; 427: 158-65.
12. Delobel P, Cazabat M, Saliou A et al. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. J Antimicrob Chemother 2013; 68: 2506-14.
13. Jung BH, Rezk NL, Bridges AS et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: 1095-104.
14. Lengauer T, Sander O, Sierra S et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol 2007; 25: 1407-10.
15. Raymond S, Delobel P, Mavigner M et al. Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol 2010; 47: 126-30.
16. Roche M, Salimi H, Duncan R et al. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology 2013; 10:43.
17. Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
18. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
19. Craig C, Lewis M, Simpson P et al. Characteristics of virus in patients with maraviroc failure while receiving maraviroc in the expanded access program A4001050. In: Abstracts of the Tenth European Meeting on HIV and Hepatitis, Barcelona, 2012. Abstract O_08, p. 10. Virology Education, Utrecht, the Netherlands.
20. De Jong JJ, De Ronde A, Keulen W et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992; 66: 6777-80.
21. Trkola A, Kuhmann SE, Strizki JM et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002; 99: 395-400.
22. Saliou A, Delobel P, Dubois M et al. Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother 2011; 55: 2831-6.
23. Garrido C, Roulet V, Chueca N et al. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J Clin Microbiol 2008; 46: 887-91.
24. Raymond S, Delobel P, Mavigner M et al. Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 2009; 47: 2292-4.
25. Raymond S, Delobel P, Chaix ML et al. Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011; 8:56.
26. Raymond S, Delobel P, Rogez S et al. Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol 2013; 51: 564-70.
27. Raymond S, Delobel P, Mavigner M et al. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 2008; 22: F11-6.
28. Poveda E, Briz V, Roulet V et al. Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. AIDS 2007; 21: 1487-90.
29. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
30. Moore JP, Kuritzkes DR. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009; 4: 118-24.
31. Recordon-Pinson P, Raymond S, Bellecave P et al. HIV-1 dynamics and coreceptor usage in maraviroc-treated patients with ongoing replication. Antimicrob Agents Chemother 2013; 57: 930-5.
32. Delobel P, Raymond S, Mavigner M et al. Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc. AIDS 2010; 24: 1382-4.